Search Within

Matthew J Matasar

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (18)
  2. Journal Article (8)
Groups
  1. Center for Hematologic Malignancies (26)
  2. Department of Medicine (26)
  3. GSK Faculty (26)
  4. Hematologic Malignancies, Division of (26)
  5. Human Oncology and Pathogenesis Program (26)
  6. Lymphoma (26)

More Groups

People
  1. Andrew Zelenetz (22)
  2. Alison Moskowitz (21)
  3. Steven Horwitz (21)
  4. Connie Batlevi (20)
  5. Ariela Noy (19)
  6. David Straus (19)

More People

Years
  1. 2023 (2)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (3)
  5. 2019 (3)
  6. 2018 (3)

More Years

Publications
  1. Blood (15)
  2. Blood Advances (3)
  3. Hematological Oncology (2)
  4. Journal of Clinical Oncology (2)
  5. Biology of Blood and Marrow Transplantation (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (18)
  2. American Society of Clinical Oncology (2)
  3. Wiley Blackwell (2)
  4. Elsevier Inc. (1)
  5. John Wiley & Sons (1)
  6. Nature Publishing Group (1)

More Publishers

Results (26)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era
    Journal Article

    Vardhana, S. A.; Sauter, C. S.; Matasar, M. J.; Zelenetz, A. D.; Galasso, N.; Woo, K. M.; Zhang, Z.; Moskowitz, C. H.
    British Journal of Haematology (2017)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era
    Meeting Abstract

    Vardhana, S. A.; Moskowitz, C. H.; Sauter, C. S.; Matasar, M. J.; Galasso, N.; Woo, K. M.; Zhang, Z. G.
    Blood (2015)

    Fulltext@MSK | Save
  • Defining the incidence and clinical impact of genomic alterations across different histologic types of lymphoma using a clinically validated comprehensive targeted sequencing assay
    Meeting Abstract

    Batlevi, C.; Rapaport, F.; Intlekofer, A. M.; Reiner, A.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, L.; Moskowitz, A. J.; Gerecitano, J. F.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Identification of actionable genomic alterations across different lymphoma histologies using a comprehensive next generation genomic sequencing clinical assay
    Meeting Abstract

    Batlevi, C.; Moskowitz, C. H.; Zelenetz, A. D.; Horwitz, S. M.; Palomba, L.; Gerecitano, J. F.; Copeland, A. R.; Hamlin, P.; Matasar, M. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save